What's in Acacia Research's pipeline?

Acacia Research has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Acacia Research's portfolio?

Top competitors by shared drug class: Rising.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/acacia.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

Acacia Research — Portfolio Competitive Intelligence Brief

Acacia Research (ACTG) pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

ACTG (NASDAQ) 1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Barhemsys	AMISULPRIDE	marketed	Dopamine-2 Receptor Antagonist [EPC]	D(2) dopamine receptor	Neuroscience	2020-01-01

Therapeutic area mix

Neuroscience · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Rising · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Acacia Research:

Cite this brief

Drug Landscape (2026). Acacia Research — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/acacia. Accessed 2026-05-13.